Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model

OncoImmunology

Volumn 5, Issue 3, 2016, Pages

  Chang, De Kuan ^a,b   Peterson, Eric ^a   Sun, Jiusong ^a   Goudie, Calum ^a   Drapkin, Ronny I ^a,c,d   Liu, Joyce F ^a,b   Matulonis, Ursula ^a   Zhu, Quan ^a,b   Marasco, Wayne A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CCR4; immunotherapy; monoclonal antibody; ovarian cancer; regulatory T cells

Indexed keywords

CHEMOKINE RECEPTOR CCR4; GAMMA INTERFERON; GELATINASE B; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; MAB2-3 IGG1; MAB2-3 IGG4; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NORMAL HUMAN; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR XENOGRAFT;

EID: 84961589082     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1090075     Document Type: Article

References (67)

1. B.W.Stewart, C.P.Wild. World Cancer Report 2014. France: WHO Press, World Health Organization
2. R.Agarwal, S.B.Kaye. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3:502-16; PMID:12835670; http://dx.doi.org/10.1038/nrc1123
3. P.J.DiSaia, J.D.Bloss. Treatment of ovarian cancer: new strategies. Gynecol Oncol 2003; 90:S24-32; PMID:12928003; http://dx.doi.org/10.1016/S0090-8258(03)00341-X
4. M.L.Disis, S.Rivkin. Future directions in the management of ovarian cancer. Hematol Oncol Clin North Am 2003; 17:1075-85; PMID:12959192; http://dx.doi.org/10.1016/S0889-8588(03)00054-6
5. M.Chatterjee, M.A.Tainsky. Autoantibodies as biomarkers for ovarian cancer. Cancer Biomark 2010; 8:187-201; PMID:22045353; http://dx.doi.org/10.3233/CBM-2011-0213.
6. J.Duraiswamy, K.M.Kaluza, G.J.Freeman, G.Coukos. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013; 73:3591-603; PMID:23633484; http://dx.doi.org/10.1158/0008-5472.CAN-12-4100
7. G.Q.Phan, J.C.Yang, R.M.Sherry, P.Hwu, S.L.Topalian, D.J.Schwartzentruber, N.P.Restifo, L.R.Haworth, C.A.Seipp, L.J.Freezer et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100:8372-7; PMID:12826605; http://dx.doi.org/10.1073/pnas.1533209100
8. F.S.Hodi, M.C.Mihm, R.J.Soiffer, F.G.Haluska, M.Butler, M.V.Seiden, T.Davis, R.Henry-Spires, S.MacRae, A.Willman et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003; 100:4712-7; PMID:12682289; http://dx.doi.org/10.1073/pnas.0830997100
9. K.C.Soares, A.A.Rucki, A.A.Wu, K.Olino, Q.Xiao, Y.Chai, A.Wamwea, E.Bigelow, E.Lutz, L.Liu et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother 2015; 38:1-11; PMID:25415283; http://dx.doi.org/10.1097/CJI.0000000000000062
10. V.K.Anagnostou, J.R.Brahmer. Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer. Clin Cancer Res 2015; 21:976-84; PMID:25733707; http://dx.doi.org/10.1158/1078-0432.CCR-14-1187
11. T.Boon, J.C.Cerottini, B.Van den Eynde, P.van der Bruggen, A.Van Pel. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12:337-65; PMID:8011285; http://dx.doi.org/10.1146/annurev.iy.12.040194.002005
12. S.Sakaguchi, T.Yamaguchi, T.Nomura, M.Ono. Regulatory T cells and immune tolerance. Cell 2008; 133:775-87; PMID:18510923; http://dx.doi.org/10.1016/j.cell.2008.05.009
13. K.J.Wood, S.Sakaguchi. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3:199-210; PMID:12658268; http://dx.doi.org/10.1038/nri1027
14. B.Valzasina, S.Piconese, C.Guiducci, M.P.Colombo. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 2006; 66:4488-95; PMID:16618776; http://dx.doi.org/10.1158/0008-5472.CAN-05-4217
15. E.Y.Woo, C.S.Chu, T.J.Goletz, K.Schlienger, H.Yeh, G.Coukos, S.C.Rubin, L.R.Kaiser, C.H.June. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61:4766-72; PMID:11406550
16. T.J.Curiel, G.Coukos, L.Zou, X.Alvarez, P.Cheng, P.Mottram, M.Evdemon-Hogan, J.R.Conejo-Garcia, L.Zhang, M.Burow et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093
17. C.Baecher-Allan, D.E.Anderson. Regulatory cells and human cancer. Semin Cancer Biol 2006; 16:98-105; PMID:16378733; http://dx.doi.org/10.1016/j.semcancer.2005.11.003
18. L.Zhang, J.R.Conejo-Garcia, D.Katsaros, P.A.Gimotty, M.Massobrio, G.Regnani, A.Makrigiannakis, H.Gray, K.Schlienger, M.N.Liebman et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177
19. K.Kurose, Y.Ohue, E.Sato, A.Yamauchi, S.Eikawa, M.Isobe, Y.Nishio, A.Uenaka, M.Oka, E.Nakayama. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760). J Thorac Oncol 2015; 10:74-83; PMID:25325779; http://dx.doi.org/10.1097/JTO.0000000000000364
20. C.C.Preston, M.J.Maurer, A.L.Oberg, D.W.Visscher, K.R.Kalli, L.C.Hartmann, E.L.Goode, K.L.Knutson. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PloS one 2013; 8:e80063; PMID:24244610; http://dx.doi.org/10.1371/journal.pone.0080063
21. D.K.Chang, J.Sui, S.Geng, A.Muvaffak, M.Bai, R.C.Fuhlbrigge, A.Lo, A.Yammanuru, L.Hubbard, J.Sheehan et al. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther 2012; 11:2451-61; PMID:22869555; http://dx.doi.org/10.1158/1535-7163.MCT-12-0278
22. D.Sugiyama, H.Nishikawa, Y.Maeda, M.Nishioka, A.Tanemura, I.Katayama, S.Ezoe, Y.Kanakura, E.Sato, Y.Fukumori et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 2013; 110:17945-50; PMID:24127572; http://dx.doi.org/10.1073/pnas.1316796110
23. J.D.Fontenot, M.A.Gavin, A.Y.Rudensky. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330-6; PMID:12612578; http://dx.doi.org/10.1038/ni904
24. P.Bruhns, B.Iannascoli, P.England, D.A.Mancardi, N.Fernandez, S.Jorieux, M.Daëron. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113:3716-25; PMID:19018092; http://dx.doi.org/10.1182/blood-2008-09-179754
25. S.Domcke, R.Sinha, D.A.Levine, C.Sander, N.Schultz. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013; 4:2126; PMID:23839242; http://dx.doi.org/10.1038/ncomms3126
26. D.A.Vignali, L.W.Collison, C.J.Workman. How regulatory T cells work. Nat Rev Immunol 2008; 8:523-32; PMID:18566595; http://dx.doi.org/10.1038/nri2343
27. J.H.Richardson, J.G.Sodroski, T.A.Waldmann, W.A.Marasco. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the α subunit of the receptor. Proc Natl Acad Sci U S A 1995; 92:3137-41; PMID:7724529; http://dx.doi.org/10.1073/pnas.92.8.3137
28. B.C.Sheu, S.M.Hsu, H.N.Ho, H.C.Lien, S.C.Huang, R.H.Lin. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001; 61:237-42; PMID:11196168
29. Y.Jacques, B.Le Mauff, F.Boeffard, A.Godard, J.P.Soulillou. A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity. J Immunol 1987; 139:2308-16; PMID:2821110
30. D.G.Cronshaw, C.Owen, Z.Brown, S.G.Ward. Activation of phosphoinositide 3-kinases by the CCR4 ligand macrophage-derived chemokine is a dispensable signal for T lymphocyte chemotaxis. J Immunol 2004; 172:7761-70; http://dx.doi.org/10.4049/jimmunol.172.12.7761
31. M.Nakagawa, R.Schmitz, W.Xiao, C.K.Goldman, W.Xu, Y.Yang, X.Yu, T.A.Waldmann, L.M.Staudt. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med 2014; 211:2497-505; PMID:25488980; http://dx.doi.org/10.1084/jem.20140987
32. T.M.Brusko, C.H.Wasserfall, M.A.Hulme, R.Cabrera, D.Schatz, M.A.Atkinson. Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation. PloS One 2009; 4:e7980; PMID:19956753; http://dx.doi.org/10.1371/journal.pone.0007980
33. C.S.De Paiva, K.C.Yoon, S.B.Pangelinan, S.Pham, L.M.Puthenparambil, E.Y.Chuang, W.J.Farley, M.E.Stern, D.Q.Li, S.C.Pflugfelder. Cleavage of functional IL-2 receptor α chain (CD25) from murine corneal and conjunctival epithelia by MMP-9. J Inflamm 2009; 6:31; PMID:19878594; http://dx.doi.org/10.1186/1476-9255-6-31
34. E.Mortier, J.Bernard, A.Plet, Y.Jacques. Natural, proteolytic release of a soluble form of human IL-15 receptor α-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 2004; 173:1681-8; PMID:15265897; http://dx.doi.org/10.4049/jimmunol.173.3.1681
35. T.Lanca, B.Silva-Santos. The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology 2012; 1:717-25; PMID:22934263; http://dx.doi.org/10.4161/onci.20068
36. W.Zou. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74; PMID:15776005; http://dx.doi.org/10.1038/nrc1586
37. T.Ishida, R.Ueda. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci 2011; 102:44-50; PMID:21044233; http://dx.doi.org/10.1111/j.1349-7006.2010.01767.x
38. R.Niwa, E.Shoji-Hosaka, M.Sakurada, T.Shinkawa, K.Uchida, K.Nakamura, K.Matsushima, R.Ueda, N.Hanai, K.Shitara. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64:2127-33; PMID:15026353; http://dx.doi.org/10.1158/0008-5472.CAN-03-2068
39. T.Han, U.M.Abdel-Motal, D.K.Chang, J.Sui, A.Muvaffak, J.Campbell, Q.Zhu, T.S.Kupper, W.A.Marasco. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. PloS one 2012; 7:e44455; PMID:22973452; http://dx.doi.org/10.1371/journal.pone.0044455
40. A.Ito, T.Ishida, H.Yano, A.Inagaki, S.Suzuki, F.Sato, H.Takino, F.Mori, M.Ri, S.Kusumoto et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother 2009; 58:1195-206; PMID:19048251; http://dx.doi.org/10.1007/s00262-008-0632-0
41. H.Yano, T.Ishida, A.Inagaki, T.Ishii, S.Kusumoto, H.Komatsu, S.Iida, A.Utsunomiya, R.Ueda. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 2007; 120:2052-7; PMID:17278106; http://dx.doi.org/10.1002/ijc.22536
42. K.Karube, K.Ohshima, T.Tsuchiya, T.Yamaguchi, R.Kawano, J.Suzumiya, A.Utsunomiya, M.Harada, M.Kikuchi. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004; 126:81-4; PMID:15198736; http://dx.doi.org/10.1111/j.1365-2141.2004.04999.x
43. X.Ni, J.L.Jorgensen, M.Goswami, P.Challagundla, W.K.Decker, Y.H.Kim, M.A.Duvic. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sezary syndrome. Clin Cancer Res 2015; 21:274-85; PMID:25376389; http://dx.doi.org/10.1158/1078-0432.CCR-14-0830
44. V.Katritch, V.Cherezov, R.C.Stevens. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci 2012; 33:17-27; PMID:22032986; http://dx.doi.org/10.1016/j.tips.2011.09.003
45. M.C.Lagerstrom, H.B.Schioth. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008; 7:339-57; PMID:18382464; http://dx.doi.org/10.1038/nrd2518
46. D.M.Rosenbaum, S.G.Rasmussen, B.K.Kobilka. The structure and function of G-protein-coupled receptors. Nature 2009; 459:356-63; PMID:19458711; http://dx.doi.org/10.1038/nature08144
47. N.Vaidehi, T.Kenakin. The role of conformational ensembles of seven transmembrane receptors in functional selectivity. Curr Opin Pharmacol 2010; 10:775-81; PMID:20933468; http://dx.doi.org/10.1016/j.coph.2010.09.004
48. J.M.Viney, D.P.Andrew, R.M.Phillips, A.Meiser, P.Patel, M.Lennartz-Walker, D.J.Cousins, N.P.Barton, D.A.Hall, J.E.Pease. Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy. J Immunol 2014; 192:3419-27; http://dx.doi.org/10.4049/jimmunol.1300232; PMID:24563252
49. S.Santulli-Marotto, K.Boakye, E.Lacy, S.J.Wu, J.Luongo, K.Kavalkovich, A.Coelho, C.M.Hogaboam, M.Ryan. Engagement of two distinct binding domains on CCL17 is required for signaling through CCR4 and establishment of localized inflammatory conditions in the lung. PloS One 2013; 8:e81465; PMID:24339934; http://dx.doi.org/10.1371/journal.pone.0081465
50. O.Boyman, M.Kovar, M.P.Rubinstein, C.D.Surh, J.Sprent. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311:1924-7; PMID:16484453; http://dx.doi.org/10.1126/science.1122927
51. D.Hannani, M.Vetizou, D.Enot, S.Rusakiewicz, N.Chaput, D.Klatzmann, M.Desbois, N.Jacquelot, N.Vimond, S.Chouaib et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 2015; 25:208-24; PMID:25582080; http://dx.doi.org/10.1038/cr.2015.3
52. C.A.Lindqvist, L.H.Christiansson, B.Simonsson, G.Enblad, U.Olsson-Stromberg, A.S.Loskog. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology 2010; 131:371-6; PMID:20518821; http://dx.doi.org/10.1111/j.1365-2567.2010.03308.x
53. S.C.Wuest, J.H.Edwan, J.F.Martin, S.Han, J.S.Perry, C.M.Cartagena, E.Matsuura, D.Maric, T.A.Waldmann, B.Bielekova. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 2011; 17:604-9; PMID:21532597; http://dx.doi.org/10.1038/nm.2365
54. H.Wiendl, C.C.Gross. Modulation of IL-2Ralpha with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol 2013; 9:394-404; PMID:23732529; http://dx.doi.org/10.1038/nrneurol.2013.95
55. C.Kudo-Saito, J.Schlom, K.Camphausen, C.N.Coleman, J.W.Hodge. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res 2005; 11:4533-44; PMID:15958639; http://dx.doi.org/10.1158/1078-0432.CCR-04-2237
56. M.A.Morse, A.C.Hobeika, T.Osada, D.Serra, D.Niedzwiecki, H.K.Lyerly, T.M.Clay. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008; 112:610-8; PMID:18519811; http://dx.doi.org/10.1182/blood-2008-01-135319
57. J.F.Curtin, M.Candolfi, T.M.Fakhouri, C.Liu, A.Alden, M.Edwards, P.R.Lowenstein, M.G.Castro. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PloS one 2008; 3:e1983; PMID:18431473; http://dx.doi.org/10.1371/journal.pone.0001983
58. N.Dilek, N.Poirier, P.Hulin, F.Coulon, C.Mary, S.Ville, H.Vie, B.Clémenceau, G.Blancho, B.Vanhove. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells. PloS one 2013; 8:e83139; PMID:24376655; http://dx.doi.org/10.1371/journal.pone.0083139
59. T.R.Simpson, F.Li, W.Montalvo-Ortiz, M.A.Sepulveda, K.Bergerhoff, F.Arce, C.Roddie, J.Y.Henry, H.Yagita, J.D.Wolchok et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210:1695-710; PMID:23897981; http://dx.doi.org/10.1084/jem.20130579
60. F.S.Hodi, M.Butler, D.A.Oble, M.V.Seiden, F.G.Haluska, A.Kruse, S.Macrae, M.Nelson, C.Canning, I.Lowy et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008; 105:3005-10; PMID:18287062; http://dx.doi.org/10.1073/pnas.0712237105
61. S.M.Ansell, A.M.Lesokhin, I.Borrello, A.Halwani, E.C.Scott, M.Gutierrez, S.J.Schuster, M.M.Millenson, D.Cattry, G.J.Freeman et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311-9; PMID:25482239; http://dx.doi.org/10.1056/NEJMoa1411087
62. J.D.Wolchok, H.Kluger, M.K.Callahan, M.A.Postow, N.A.Rizvi, A.M.Lesokhin, N.H.Segal, C.E.Ariyan, R.A.Gordon, K.Reed et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
63. A.Swaika, W.A.Hammond, R.W.Joseph. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 2015 Oct; 67(2 Pt A):4-17; PMID:25749122; http://dx.doi.org/10.1016/j.molimm.2015.02.009
64. T.C.Nesspor, T.S.Raju, C.N.Chin, O.Vafa, R.J.Brezski. Avidity confers FcgammaR binding and immune effector function to aglycosylated immunoglobulin G1. J Mol Recognit 2012; 25:147-54; PMID:22407978; http://dx.doi.org/10.1002/jmr.2155
65. J.J.Severson, H.S.Serracino, V.Mateescu, C.D.Raeburn, R.C.McIntyre, S.B.Sams, B.R.Haugen, J.D.French. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res 2015; 3(6):620-30; PMID:25701326; http://dx.doi.org/10.1158/2326-6066.CIR-14-0201
66. S.Y.Choi, D.Lin, P.W.Gout, C.C.Collins, Y.Xu, Y.Wang. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv Drug Deliv Rev 2014; 79-80:222-37; PMID:25305336; http://dx.doi.org/10.1016/j.addr.2014.09.009.
67. R.Das, R.Verma, M.Sznol, C.S.Boddupalli, S.N.Gettinger, H.Kluger, M.Callahan, J.D.Wolchok, R.Halaban, M.V.Dhodapkar et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015; 194:950-9; http://dx.doi.org/10.4049/jimmunol.1401686